Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Medical Officer

Executive Chairman

Chief Executive Officer

Chief Commercial Officer

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-12-27	Premium	back to issuer	Premium	Premium	Premium	-
2023-12-27	Premium	back to issuer	Premium	Premium	Premium	-
2023-12-26	Premium	sold	Premium	Premium	Premium	-
2023-12-26	Premium	sold	Premium	Premium	Premium	-
2023-12-26	Premium	sold	Premium	Premium	Premium	-
2023-12-26	Premium	sold	Premium	Premium	Premium	-
2023-12-22	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-12-22	Premium	sold	Premium	Premium	Premium	Executive Chairman
2023-12-22	Premium	sold	Premium	Premium	Premium	Executive Chairman
2023-12-22	Premium	sold	Premium	Premium	Premium	Executive Chairman
2023-12-22	Premium	sold	Premium	Premium	Premium	Executive Chairman
2023-12-22	Premium	sold	Premium	Premium	Premium	Executive Chairman
2023-12-22	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2023-12-22	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2023-12-22	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-12-22	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-12-18	Premium	sold	Premium	Premium	Premium	-
2023-11-06	Premium	gifted	Premium	Premium	Premium	Chief Executive Officer
2023-11-03	Premium	gifted	Premium	Premium	Premium	Executive Chairman
2023-10-31	Premium	gifted	Premium	Premium	Premium	Chief Medical Officer
2023-03-21	Premium	acquired	Premium	Premium	Premium	-
2022-11-29	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2022-11-28	Premium	bought	Premium	Premium	Premium	-
2022-11-25	Premium	bought	Premium	Premium	Premium	-
2022-11-23	Premium	bought	Premium	Premium	Premium	-

PNT - POINT Biopharma Global Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for PNT